Antonio Requena, M.D., Ph.D.

Biography

Dr. Antonio Requena, MD, is Assistant Professor at Rey Juan Carlos University in the Department of Obstetrics and Gynecology; Director Master’s Degree in Biology and Technology Applied to Assisted Human Reproduction IVI Madrid-European University of Madrid; Former Executive Manager of IVI Congress; IVI Madrid Director and Chief Medical Officer of IVIRMA Global. He graduated from the Complutense University of Madrid in Medicine and he completed his training in Gynecology and Obstetrics at the Autonoma University in Madrid.

He went on to pursue a pre-doctoral training in invitro oocyte maturation at John Eppig’s laboratory (Bar Harbour, Maine, USA) and finally he achieved his PhD in Medicine from Rey Juan Carlos University in Madrid. Dr. Requena completed his training by studying several masters: Management Development at ESADE Business School, Management Program in Health Institutions at IESE Business School and Innovation and Leadership in Fertility in IE Business School.

He has participated as a tutor in several projects financed by public entities, such as “Influence of glucose metabolism during oocyte maturation in cellular apoptosis. Clinical application in the diabeticpatient” at Autonoma University in Madrid.

He is active in the Spanish Society of Fertility (SEF) and also attends the European Society of Human Reproduction and Embryology (ESHRE).
Dr. Requena has been invited to speak nationally and internationally and has authored and contributed in over 40 peer reviewed publications, published chapters and abstracts. He also serves as Ad Hoc Reviewer for the Reproductive Biomedicine Online, Human Reproduction, Fertility and
Sterility, and as the editor for a textbook on Reproductive Medicine. His research interests include Endocrinology, Ovarian Stimulations, and genetics in Reproductive Medicine.

Education and Training

Graduated in Medicine	Complutense University (Madrid) (1989)
Pre-doctoral training in in-vitro oocyte maturation	John Eppig’s laboratory (Bar Harbour,Maine, USA) (1998)
Program of Management Development	(ESADE Business School) (2009)
PhD in Medicine	Rey Juan Carlos University (Madrid) (2014)
Advanced Management Program in Health Institutions	(IESE Business School) (2015)
Innovation and Leadership.	(IE Business School) (2016)

Publications

Is Medroxiprogesterone acetate an adequate alternative to GnRH-antagonist in oocyte vitrification for social fertility preservation and preimplantation genetic testing for aneuploidy cycles?
Giles J, Cruz M, Cobo A, Vidal C, Requena A, Remohi J, Bosch E

Reproductive BioMedicine Online Available online 1 May 2023 In press. 2023 doi:

The role of thrombophilias in reproduction: A swot analysis.
Fabregues F, Antonio García-Velasco J, Llácer J, Requena A, Ángel Checa M, Bellver J, José Espinós J

Eur J Obstet Gynecol Reprod Biol. 2023 Jan;280:12-21. doi: 10.1016/j.ejogrb.2022.10.024. Epub 2022 Oct 31.. 2023 doi:

The type of SARS-CoV-2 vaccine does not affect ovarian function in assisted reproduction cycle.
Requena A, Vergara V, González-Ravina C, Ruiz ME, Cruz M

Fertil Steril. 2022 Dec 17:S0015-0282(22)02109-4. doi: 10.1016/j.fertnstert.2022.12.022. Online ahead of print.. 2022 doi:

Impact of parental chromosomal polymorphisms on the incidence of congenital anomalies and perinatal complications in a cohort of newborns conceived after ICSI + PGT-A.
Rodriguez F, Cruz M, Requena A

Reprod Biol Endocrinol.. Sep. 2022 doi: 10.1186/s12958-022-01012-2.

Adenomyosis decreases the live birth rate but may not affect perinatal outcomes in assisted reproductive cycles.
Trinchant R, Cruz M, Requena A

Int J Gynaecol Obstet. 2022 May 6. Online ahead of print. 2022 doi: 10.1002/ijgo.14256

Presentations

Klimczak AM Herlihy NS Kim JG Hanson BM Osman EK Tiegs AW Marie D Werner Kaser DJ Requena A Scott RT P-744 USE OF MEDROXYPROGESTERONE ACETATE (MPA) IN DONOR CYCLES DECREASES MEDICATION COSTS. Presented at 76th American Society of Reproductive Medicine Scientific Congress, Virtual congress, October 17-21,2020

Prados N González-Ravina C Vergara V Javier Herrero Cruz M Requena A P-980 RISK FACTOR ANALYSIS FOR SARS-COV-2 SEROPOSITIVITY WITHIN ASSISTED REPRODUCTIVE. Presented at 76th American Society of Reproductive Medicine Scientific Congress, Virtual congress, October 17-21,2020

Cruz M Vergara V Requena A P-857 TYPE OF FOLLITROPIN ALFA FOR OVARIAN STIMULATION WITH MEDROXYPROGESTERONE ACETATE DOES NOT AFFECT CLINICAL OUTCOMES IN A DONOR-RECIPIENT PROGRAM. Presented at 76th American Society of Reproductive Medicine Scientific Congress, Virtual congress, October 17-21,2020

Rodriguez Valderrama F Palomino MC Pla Victori J Requena A Chromosomal abnormalities in males,but not chromosomal polymorphisms,affect the preterm delivery rate in ICSI+PGT cycles. Presented at the 36th annual meeting of the European Society of Human Reproduction and Embryology, Copenhagen,Denmark, July 5-8,2020

María Cruz Hennzen E Requena A O-156 Pituitary supression is not necessary for blocking LH surge during luteal-phase stimulation. Presented at the 36th annual meeting of the European Society of Human Reproduction and Embryology, Copenhagen,Denmark, July 5-8,2020

González-Ravina Vergara V Cruz M Prados N Requena A O-146 Is COVID-19 symptomatic triage enough? The limited value of serological testing. Presented at the 36th annual meeting of the European Society of Human Reproduction and Embryology, Copenhagen,Denmark, July 5-8,2020

Cruz M Alecsandru D Garcia Velasco J Requena A Use of granulocyte colony-stimulating factor during an assisted reproductive treatment does not increase the risk of birth defects. Presented at the 33rd annual meeting of the European Society of Human Reproduction and Embryology, Geneva,Switerland, July 1-4,2018

Calonge M Garrido N Cobo A Gonzalez-Valdes F Morbeck D Requena A Troncoso C Quantifying the parameters affecting the success of egg donor program: A predictive model and optimization tool. , , July 2-5 ,2017

González-Ravina C Cruz M Rubio C Fernández-Sánchez M Oquiñena E Ferrando R Requena A Polymorphic chromosome variants,human inversions,and their functional consequences in male infertility. , , July 2-5 ,2017

Rubio Lluesa C Cruz M González-Ravina C Fernández-Sánchez M Oquiñena E Requena A Polymorphism on chromosome 21 does not affect ovarian reserve but clinical outcomes after in vitro fertilization treatments. , , July 2-5 ,2017

Sánchez M Pacheco A Cruz M Requena A Assessment of sperm ploidy status by flow cytommetry correlates to embryo quality 2017

Vergara Bravo V Cruz M Goyri E Requena A Pituitary suppression protocol does affect clinical outcomes in egg donation cycles 2017

Fertility Researchers

OUR INVESTIGATORS

Biography

Education and Training

Publications

Presentations

Videos